Drug
Recombinant Human Porphobilinogen Deaminase
Recombinant Human Porphobilinogen Deaminase: highest development phase Phase 2/3, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| recombinant human porphobilinogen deaminase (Porphozym) NCT00418795 | Phase 2/3 | Acute Intermittent Porphyria |
Latest
No recent events.
Follow Recombinant Human Porphobilinogen Deaminase on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.